Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN), a CNS-focused biopharmaceutical company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace.
The presentation will be accessible via live audio webcast through the company’s website investor relations section, with a replay available for 60 days post-conference. Investors seeking meetings with management should contact the conference coordinator.
Supernus Pharmaceuticals (Nasdaq: SUPN), una società biofarmaceutica focalizzata sul sistema nervoso centrale, ha annunciato la sua partecipazione al 36° Conferenza Sanitaria Annuale Piper Sandler. Il presidente e CEO Jack A. Khattar parteciperà a una chiacchierata informale il 4 dicembre 2024, alle 12:00 ET presso il Lotte New York Palace.
La presentazione sarà accessibile tramite webcast audio dal vivo nella sezione relazioni con gli investitori del sito web dell’azienda, con una riproduzione disponibile per 60 giorni dopo la conferenza. Gli investitori che desiderano incontri con la direzione devono contattare il coordinatore della conferenza.
Supernus Pharmaceuticals (Nasdaq: SUPN), una compañía biofarmacéutica enfocada en el sistema nervioso central, anunció su participación en la 36ª Conferencia Anual de Salud Piper Sandler. El presidente y CEO Jack A. Khattar participará en una charla informal el 4 de diciembre de 2024, a las 12:00 p.m. ET en el Lotte New York Palace.
La presentación será accesible a través de una transmisión de audio en vivo en la sección de relaciones con inversores del sitio web de la empresa, con una repetición disponible por 60 días después de la conferencia. Los inversores que deseen reuniones con la dirección deben contactar al coordinador de la conferencia.
Supernus Pharmaceuticals (Nasdaq: SUPN)은 CNS(중추신경계)에 중점을 둔 바이오 제약 회사로, 제36회 연례 파이퍼 샌들러 헬스케어 콘퍼런스에 참가한다고 발표했습니다. 사장 겸 CEO인 Jack A. Khattar는 2024년 12월 4일 오후 12:00 ET에 Lotte New York Palace에서 포럼 대화에 참여할 예정입니다.
프레젠테이션은 회사 웹사이트의 투자자 관계 섹션을 통해 생중계 오디오 웹캐스트로 제공되며, 컨퍼런스 후 60일 동안 다시 시청할 수 있습니다. 관리진과의 미팅을 원하는 투자자는 컨퍼런스 코디네이터에게 연락해야 합니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une société bio-pharmaceutique spécialisée dans le système nerveux central, a annoncé sa participation à la 36e Conférence Annuelle de Santé Piper Sandler. Le président et PDG Jack A. Khattar participera à une discussion informelle le 4 décembre 2024 à 12h00 ET au Lotte New York Palace.
La présentation sera accessible en direct via un webinaire audio sur la section des relations investisseurs du site web de l’entreprise, avec une rediffusion disponible pendant 60 jours après la conférence. Les investisseurs souhaitant des réunions avec la direction doivent contacter le coordinateur de la conférence.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen mit Fokus auf das zentrale Nervensystem, hat seine Teilnahme an der 36. jährlichen Piper Sandler Gesundheitskonferenz angekündigt. Präsident und CEO Jack A. Khattar wird am 4. Dezember 2024 um 12:00 Uhr ET im Lotte New York Palace an einem informellen Gespräch teilnehmen.
Die Präsentation wird über einen Live-Audio-Webcast über den Bereich für Investorenbeziehungen auf der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 60 Tage nach der Konferenz verfügbar ist. Investoren, die Meetings mit der Geschäftsleitung wünschen, sollten den Konferenzkoordinator kontaktieren.
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City.
Investors interested in arranging a meeting with company management during the conference should contact the Piper Sandler conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company’s website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel, first in class CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s reporting on preliminary and exploratory open label clinical study on SPN-820, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s ability to conduct and progress product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates including SPN-820 and SPN 830; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates including SPN-820; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates including SPN-820; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
Peter.Vozzo@westwicke.com
FAQ
When is Supernus Pharmaceuticals (SUPN) presenting at the Piper Sandler Healthcare Conference 2024?
Supernus Pharmaceuticals will present on Wednesday, December 4, 2024, at 12:00 p.m. ET.
Where can I watch Supernus Pharmaceuticals’ (SUPN) Piper Sandler Conference presentation?
The presentation can be accessed through the Events & Presentations section in the Investor Relations area of Supernus’ website at www.supernus.com.
How long will Supernus Pharmaceuticals’ (SUPN) Piper Sandler Conference webcast be available?
An archived replay of the webcast will be available for 60 days on the company’s website following the conference.
Where is the 2024 Piper Sandler Healthcare Conference being held for Supernus (SUPN)?
The conference is being held at the Lotte New York Palace in New York City.
